Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase
about
Genealogical evidence for positive selection in the nef gene of HIV-1The dynamics of human cytomegalovirus replication in vivoIncreased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive personsOptimal timing and duration of induction therapy for HIV-1 infectionSimple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutationsA multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variantsHighly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in JapanA fossil record of zidovudine resistance in transmitted isolates of HIV-1Harnessing DNA synthesis to develop rapid responses to emerging and pandemic pathogens.The Effects of Population Size Histories on Estimates of Selection Coefficients from Time-Series Genetic Data.A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression.Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.Modeling and estimation of kinetic parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments.Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.Genotypic testing for human immunodeficiency virus type 1 drug resistance.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesisVirulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure.Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay.Population dynamics of HIV-1 inferred from gene sequences.Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children.A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.What do mathematical models tell us about the emergence and spread of drug-resistant HIV?Evolution of drug-resistant viral populations during interruption of antiretroviral therapyTransmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model.pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D.Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation.Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population.Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses.Design requirements for interfering particles to maintain coadaptive stability with HIV-1.HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations.Clinical significance of human immunodeficiency virus type 1 replication fitness.
P2860
Q27473192-B76BB027-482D-401D-A906-02A2C6DE7A06Q28141142-08D70F2A-A812-4B4A-BF51-17266196F09EQ28363547-0FE1B79C-26C6-4B37-9188-BB6BDFB520C3Q28469250-0856D3E6-B759-4A63-9AA9-9E2AB17CDBF8Q28469253-1DEB5433-655D-452C-B07A-D4397D729261Q28473678-08E00B50-8F3D-46BC-AF03-536D176994A8Q28537608-75F60B6D-CE96-4A8C-B166-454977B9F33EQ28775685-2C84A4EC-6417-44EA-8FF0-54D1070E556EQ30428799-7AD75B4E-C06E-4D55-AE2E-E41325590705Q31123060-FFFBF6CB-5E5D-44F4-A617-316C541C4579Q33604871-E741EA15-3A30-4163-84E5-383DD3D053E8Q33737755-B949849A-A9EB-4CE2-B67B-E254CDAFA674Q33785915-614E05A2-10E9-4BC2-B727-AB92DCDD33EEQ33797464-E0934A54-F6AC-4C54-B8D3-BDF4C5ACEE6DQ33820365-323DD03B-7D47-4553-AFC9-E4415578FA21Q33826453-BB0F8246-35F4-47E9-9E95-36CD7D22685EQ33906239-175AFC36-9AE7-4DCD-8E56-016F9F6BDE94Q33979107-ECCDFE01-7BD4-4612-A3A2-07156FAFC370Q34010283-C2AE3070-05B1-494C-97A6-11B08F7E92BAQ34339657-4F583658-3F24-45A7-AD2A-88525A36A18BQ34342200-9284D7EB-9F8D-4733-AECC-613DAF8DE148Q34434646-62ADAF4D-8328-4A87-BE77-BBB7FB0C7BB4Q34490344-D23D6DCD-8A05-464C-B22F-1B12A945E5BAQ34803017-93502AAF-8312-4407-A137-3E858BE27807Q34976902-5A4CC895-CB9B-4F2E-B6FE-E98FF93EE620Q34989198-3CD3934E-A8BD-4B9C-9596-A595BD8722D1Q35077423-CD64BA33-D78A-462C-AE93-267AB75BC4D4Q35122204-EA04C02A-EB1B-4562-8E1D-69E98D573B3EQ35156768-87C1C24F-F2FB-4353-952C-F132F6D75B59Q35742512-2AE2E092-BA23-4A98-B7CE-08527B4A9809Q35784897-9DAE55DD-2858-4726-9CC3-F962F3F7CAB7Q35874788-0F044888-76D1-47D0-BA88-214CD7B965B2Q35890953-F745C877-FA6A-4646-9E39-08B5FE1D5E5AQ35899105-70CDBCF8-72D7-497C-9C50-34432831E462Q36025234-9A960638-EB22-4BC7-B1B6-30D1BED0444DQ36376216-BFB78BAC-E5DD-4E0F-A62A-5CCE8D2D9E17Q36607437-80F064BD-8B9E-42FC-AD99-6600429C0A22Q36696351-36636D0D-DC3E-497D-893D-72F34DAB2201Q36949610-1847002A-B8BE-4AB2-B234-13C58D812ACAQ36969857-DE0E5323-E183-4538-A893-702F5835FD7E
P2860
Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Human immunodeficiency virus f ...... n 215 of reverse transcriptase
@ast
Human immunodeficiency virus f ...... n 215 of reverse transcriptase
@en
type
label
Human immunodeficiency virus f ...... n 215 of reverse transcriptase
@ast
Human immunodeficiency virus f ...... n 215 of reverse transcriptase
@en
prefLabel
Human immunodeficiency virus f ...... n 215 of reverse transcriptase
@ast
Human immunodeficiency virus f ...... n 215 of reverse transcriptase
@en
P2093
P2860
P1433
P1476
Human immunodeficiency virus f ...... n 215 of reverse transcriptase
@en
P2093
P2860
P304
P407
P577
1996-08-01T00:00:00Z